Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE vs DIGOXIN PEDIATRIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
Inhibits sodium-potassium ATPase, increasing intracellular sodium, which promotes calcium influx via sodium-calcium exchanger, enhancing cardiac contractility. Also increases vagal tone, slowing AV conduction.
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
Heart failure (FDA-approved for pediatric patients with heart failure),Atrial fibrillation (off-label for rate control in pediatric patients)
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
For pediatric patients, digoxin pediatric dosing is weight-based; no standard adult dose. Typical pediatric loading dose: 10-12 mcg/kg orally divided every 6-8 hours, with maintenance: 5-10 mcg/kg/day divided every 12 hours. For infants <1 month, loading: 10-15 mcg/kg, maintenance: 4-6 mcg/kg/day. For children 1-24 months, loading: 15-20 mcg/kg, maintenance: 5-8 mcg/kg/day. For children >2 years, loading: 10-15 mcg/kg, maintenance: 3-5 mcg/kg/day.
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Terminal elimination half-life in neonates is 35-70 hours, infants 18-30 hours, children 12-30 hours, and adults 36-48 hours; prolonged in renal impairment and hypothyroidism.
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Primarily renally excreted unchanged; minimal hepatic metabolism (mostly via reduction, hydrolysis, and conjugation in older children).
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
Renal excretion accounts for 50-70% of elimination as unchanged drug; biliary/fecal excretion accounts for 30-40%, primarily as metabolites; enterohepatic recirculation occurs.
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
25% bound to serum albumin; binding decreases in uremia and hyperbilirubinemia.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
Vd: 6-10 L/kg in infants and children, 5-7 L/kg in adults; large Vd indicates extensive tissue binding, particularly to cardiac muscle (Na+/K+-ATPase).
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
Oral: 60-80% (elixir 70-85%, tablets 60-75%); IM: 70-85% (but erratic absorption and pain limit use); IV: 100%.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
Digoxin is primarily renally excreted. For pediatric patients, if GFR <30 m L/min/1.73m2, reduce maintenance dose by 50% and monitor serum levels. For GFR 30-60, reduce dose by 25-50%. In neonates with renal impairment, dose reduction proportional to creatinine clearance.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
Digoxin is minimally hepatically metabolized; no dose adjustment required for hepatic impairment. However, in Child-Pugh class C, monitor levels due to potential altered distribution.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
See standard_dosing. Weight-based dosing: total digitalizing dose (TDD) and maintenance as above. For premature infants, TDD 10-15 mcg/kg, maintenance 3-5 mcg/kg/day divided q12h. For full term neonates, TDD 15-20 mcg/kg, maintenance 5-7 mcg/kg/day. For infants 1-24 months, TDD 20-25 mcg/kg, maintenance 7-10 mcg/kg/day. For children 2-10 years, TDD 10-15 mcg/kg, maintenance 5-7 mcg/kg/day. For children >10 years, TDD 10-15 mcg/kg, maintenance 3-5 mcg/kg/day. Divide TDD into 3-4 doses every 6-8 hours. Maintenance started 12 hours after last loading dose.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
Not applicable for pediatric formulation. For elderly, use adult digoxin dosing with caution: reduced renal function may require lower maintenance doses. Typical adult maintenance: 0.0625-0.25 mg daily based on renal function and lean body mass.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Toxicity can be life-threatening. Use caution in renal impairment, electrolyte disturbances (hypokalemia, hypomagnesemia, hypercalcemia). Narrow therapeutic index requires monitoring.
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Monitor serum digoxin levels, renal function, electrolytes (potassium, magnesium, calcium). Risk of arrhythmias (including ventricular fibrillation, bradycardia, AV block). Use with caution in patients with thyroid disease, acute myocardial infarction, or myocarditis.
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
Ventricular fibrillation, hypersensitivity to digitalis preparations, hypokalemia (uncorrected), hypercalcemia (uncorrected), AV block (second or third degree) unless pacemaker present.
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
High-fiber foods may decrease absorption; take digoxin 1 hour before or 2 hours after meals. Avoid natural licorice, which can cause hypokalemia and increase toxicity. Maintain consistent dietary potassium intake.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
Digoxin crosses the placenta. First trimester: No increased risk of major malformations reported in human studies. Second/third trimester: Potential for fetal toxicity (e.g., bradycardia, cardiac arrhythmias) at maternal toxic doses. No known teratogenicity at therapeutic doses.
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
Digoxin is excreted into breast milk in low concentrations. M/P ratio approximately 0.6–0.9. Infant dose via milk is <1% of maternal weight-adjusted dose, unlikely to cause adverse effects in term infants. Caution in preterm or neonates with renal impairment.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
During pregnancy, increased volume of distribution and renal clearance may reduce serum digoxin levels. Dose adjustments may be required based on therapeutic drug monitoring; typical dose increase of 20–30% in third trimester. Postpartum, reduce dose to prepregnancy level to avoid toxicity.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
Monitor serum digoxin levels (therapeutic range 0.5-2 ng/m L) and renal function, especially in neonates. Correct hypokalemia, hypomagnesemia, and hypercalcemia before administration to reduce toxicity risk. Use with caution in patients with WPW, hypertrophic cardiomyopathy, or incomplete heart block. Dosing in infants and children is based on weight and renal function.
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
Take exactly as prescribed; do not double up doses.,Monitor for signs of toxicity: nausea, vomiting, vision changes (yellow-green halos), arrhythmias.,Keep medication out of reach of children; immediate medical attention if overdose suspected.,Do not stop abruptly without consulting healthcare provider.,Inform healthcare provider of all medications, including OTC and herbal supplements.
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
"Eflornithine, an ornithine decarboxylase inhibitor used in the treatment of African trypanosomiasis and hirsutism, may reduce the therapeutic efficacy of digoxin, a cardiotonic glycoside used for heart failure and atrial fibrillation. The proposed mechanism involves eflornithine-induced alterations in gastrointestinal motility or absorption, potentially decreasing digoxin bioavailability. This could lead to subtherapeutic digoxin levels, diminished inotropic and chronotropic effects, and increased risk of arrhythmias or worsening heart failure."
"Osimertinib, a tyrosine kinase inhibitor used in non-small cell lung cancer, can inhibit P-glycoprotein (P-gp) transport in the gastrointestinal tract and kidneys, leading to increased absorption and reduced renal clearance of digoxin. This elevation in serum digoxin concentration heightens the risk of digoxin toxicity, including cardiac arrhythmias (e.g., bradycardia, atrial tachycardia with block) and gastrointestinal symptoms such as nausea and vomiting. Clinical monitoring for digoxin toxicity is warranted, especially when initiating or adjusting osimertinib therapy."
"Lenvatinib, a tyrosine kinase inhibitor, may reduce the therapeutic efficacy of digoxin by interfering with its cardiotonic effects. This interaction could lead to decreased inotropic support in patients with heart failure, potentially worsening cardiac function and clinical outcomes. The clinical consequence is a possible loss of rate control in atrial fibrillation or diminished contractility in systolic dysfunction."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE vs DIGOXIN PEDIATRIC, answered by our medical review team.
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. DIGOXIN PEDIATRIC is a Cardiac Glycoside that works by Inhibits sodium-potassium ATPase, increasing intracellular sodium, which promotes calcium influx via sodium-calcium exchanger, enhancing cardiac contractility. Also increases vagal tone, slowing AV conduction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE and DIGOXIN PEDIATRIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of DIGOXIN PEDIATRIC is: For pediatric patients, digoxin pediatric dosing is weight-based; no standard adult dose. Typical pediatric loading dose: 10-12 mcg/kg orally divided every 6-8 hours, with maintenance: 5-10 mcg/kg/day divided every 12 hours. For infants <1 month, loading: 10-15 mcg/kg, maintenance: 4-6 mcg/kg/day. For children 1-24 months, loading: 15-20 mcg/kg, maintenance: 5-8 mcg/kg/day. For children >2 years, loading: 10-15 mcg/kg, maintenance: 3-5 mcg/kg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE and DIGOXIN PEDIATRIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . DIGOXIN PEDIATRIC is classified as Category A/B. Digoxin crosses the placenta. First trimester: No increased risk of major malformations reported in human studies. Second/third trimester: Potential for fetal toxicity (e.g., brady. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.